This article is more than 5 years old. Information may no longer be current.
Influx of Data Sets Pace for the Year Ahead
The International Liver Congress in April was full of first reports on new therapies and drug combinations to treat hepatitis C virus. Alessio Aghemo, MD, PhD, a European Association for the Study of the Liver governing board member, summed it up best: “Overall, I would say the incredible data from the ILC 2014 make the future bright for almost all of our patients.” Editor’s note: Watch Aghemo’s video wrap-up on Healio.com/HCV.
This month’s Take Home column features expert insight from attendees of ILC 2014, including HCV Next Editorial Board member Jordan J. Feld, MD, MPH. Turn to page 30 to read about their thoughts on new HCV guidelines from the World Health Organization, and results from TURQUOISE-II, RESTORE, ION-3, and more.
The rest of this issue also features exciting content about innovative trends in treatment. The Cover Story provides an in-depth look at noninvasive alternatives to the liver biopsy. This month’s feature details the history of HCV, from its discovery to the innovations that are happening today. Hellen Chiao, MD, and HCV Next Editorial Board member Catherine T. Frenette, MD, examine the important topic of solid organ transplantation in HCV-infected patients. Side effects of interferon and ribavirin treatment are the focus of the HCV Rx. Ira M. Jacobson, MD, and Michael S. Saag, MD, discuss the importance of collaboration in our Ask the Chief Medical Editors column. We also get to know Paul Martin, MD, who discusses the rapid evolution and progress made in HCV treatment over the last few years.
We at HCV Next welcome your ideas and submissions on the topics that matter most to your practice. Feel free to contact us directly at the email address below with any suggestions.
— Katie Kalvaitis
Executive Editor, HCV Next
kkalvaitis@slackinc.com